A Study of Baricitinib (LY3009104) in Participants With Primary Biliary Cholangitis Who do Not Respond or Cannot Take UDCA

NCT03742973 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

2

Enrollment

INDUSTRY

Sponsor class

Stopped Study was terminated due to enrollment futility.

Conditions

Primary Biliary Cholangitis

Interventions

DRUG: Baricitinib
DRUG: Placebo

Sponsor

Eli Lilly and Company